Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 21, 2024 07:00 ET
|
Mineralys Therapeutics, Inc.
– Enrollment in the two pivotal trials of lorundrostat for the treatment of uHTN or rHTN is on track, with topline data expected for Advance-HTN trial in Q4 2024 and Launch-HTN trial in 2H 2025 – –...
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024
March 13, 2024 16:05 ET
|
Mineralys Therapeutics, Inc.
RADNOR, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension,...
Mineralys Therapeutics Announces $120 Million Private Placement Financing
February 08, 2024 08:00 ET
|
Mineralys Therapeutics, Inc.
RADNOR, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic...
Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference
January 29, 2024 16:05 ET
|
Mineralys Therapeutics, Inc.
RADNOR, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic...
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer
January 04, 2024 16:05 ET
|
Mineralys Therapeutics, Inc.
RADNOR, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic...
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
December 21, 2023 16:05 ET
|
Mineralys Therapeutics, Inc.
– Topline data from confirmatory Launch-HTN trial expected in 2H 2025 – – Topline data from ongoing Advance-HTN pivotal trial expected in 2H 2024 – RADNOR, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) --...
Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023
November 11, 2023 11:30 ET
|
Mineralys Therapeutics, Inc.
– New analysis on serum leptin levels among patients in the Target-HTN Phase 2 trial adds to emerging evidence of positive feedback loop linking obesity, leptin and aldosterone – – Excess aldosterone...
Mineralys Therapeutics to Participate in Three Upcoming Conferences
November 09, 2023 16:05 ET
|
Mineralys Therapeutics, Inc.
RADNOR, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic...
Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 07, 2023 16:05 ET
|
Mineralys Therapeutics, Inc.
– On track to initiate planned Phase 3 pivotal Launch-HTN trial of lorundrostat to treat patients with uncontrolled or resistant hypertension in 2H 2023 – – Expect to initiate planned Phase 2...
Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting
November 02, 2023 10:00 ET
|
Mineralys Therapeutics, Inc.
– Analysis further supports obesity-associated dysregulated aldosterone as an endotype predictive of enhanced response to lorundrostat treatment in patients with uncontrolled or treatment-resistant...